Investigating how ZEB1 contributes to cancer treatment resistance
The Role of ZEB1 in promoting therapeutic resistance through its interaction with 53BP1
['FUNDING_R01'] · UNIVERSITY OF VIRGINIA · NIH-11010329
This study is looking at how a protein called ZEB1 helps cancer cells fix their damaged DNA and how it works with another protein to affect cancer treatment, with the goal of finding better ways to help patients with certain types of cancer.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF VIRGINIA (nih funded) |
| Locations | 1 site (CHARLOTTESVILLE, UNITED STATES) |
| Trial ID | NIH-11010329 on ClinicalTrials.gov |
What this research studies
This research explores the role of ZEB1, a protein involved in cancer progression, in the repair of DNA damage in cancer cells. It focuses on how ZEB1 interacts with another protein, 53BP1, to influence the effectiveness of anti-cancer therapies. By understanding these mechanisms, the research aims to identify potential targets for improving treatment outcomes for patients with certain types of cancer. The study employs various laboratory techniques to analyze DNA repair processes and their implications for cancer resistance.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with breast cancer or those with BRCA1/2 mutations who are undergoing anti-cancer therapies.
Not a fit: Patients with cancers unrelated to BRCA mutations or those not undergoing current cancer treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for overcoming resistance to cancer therapies, potentially improving treatment outcomes for patients.
How similar studies have performed: Previous research has shown that targeting DNA repair mechanisms can enhance the effectiveness of cancer treatments, suggesting that this approach may yield significant insights.
Where this research is happening
CHARLOTTESVILLE, UNITED STATES
- UNIVERSITY OF VIRGINIA — CHARLOTTESVILLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LARNER, JAMES M — UNIVERSITY OF VIRGINIA
- Study coordinator: LARNER, JAMES M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy